Status:

COMPLETED

Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Lead Sponsor:

University College, London

Collaborating Sponsors:

Cancer Research UK

Conditions:

Chemotherapeutic Agent Toxicity

Lymphoma

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as methotrexate and leucovorin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Gl...

Detailed Description

OBJECTIVES: Primary * To determine the dose-limiting toxicity of methotrexate (MTX) when given in combination with glucarpidase in patients with newly diagnosed primary CNS lymphoma (PCNSL). * To de...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed newly diagnosed primary CNS lymphoma (PCNSL)
  • Previously untreated disease
  • Diffuse large B-cell lymphoma histology
  • Must be clinically eligible to receive standard 3 g/m² methotrexate if outside trial
  • No clinically significant effusions or edema
  • PATIENT CHARACTERISTICS:
  • Inclusion criteria:
  • ECOG performance status 0-3
  • Neutrophils ≥ 1 x 10\^9/L
  • Platelet count ≥ 100 x 10\^9/L
  • Bilirubin \< 1.5 times upper limit of normal
  • Glomerular filtration rate (initially measured by EDTA/isotope method) ≥ 50 mL/min
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 6 months after completion of study therapy
  • Exclusion criteria:
  • HIV positivity
  • Dementia or neurological dysfunction not considered to be due to the PCNSL
  • Other serious or uncontrolled medical conditions
  • Prior malignancy, except adequately treated nonmelanoma skin cancer or carcinoma in situ
  • PRIOR CONCURRENT THERAPY:
  • No prior cytotoxic chemotherapy
  • No concurrent prophylactic antibiotics
  • No concurrent co-trimoxazole

Exclusion

    Key Trial Info

    Start Date :

    July 1 2008

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    July 1 2011

    Estimated Enrollment :

    4 Patients enrolled

    Trial Details

    Trial ID

    NCT00727831

    Start Date

    July 1 2008

    End Date

    July 1 2011

    Last Update

    January 27 2014

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Leeds General Infirmary

    Leeds, England, United Kingdom, LS1 3EX

    2

    Torbay Hospital

    Torquay, England, United Kingdom, TQ2 7AA

    Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | DecenTrialz